TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05887440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: isokinetic strength training of knee extensor and flexor muscles
Description: Patients underwent an isokinetic strength training program with 3 sessions per week during five weeks.~Program consists of excentric contraction of knee flexor and extensor muscles (4 x 7 Contractions at 30°/s) and concentric contractions at maximal speed where patients can perform 40% of his maximal isometric torque for knee flexor and extensor muscles (2x10 for knee flexors and 2x10 for knee extensors)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: isokinetic strength training of knee extensor and flexor muscles
Description: Patients underwent an isokinetic strength training program with 3 sessions per week during five weeks.~Program consists of excentric contraction of knee flexor and extensor muscles (4 x 7 Contractions at 30°/s) and concentric contractions at maximal speed where patients can perform 40% of his maximal isometric torque for knee flexor and extensor muscles (2x10 for knee flexors and 2x10 for knee extensors)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: isokinetic strength training of knee extensor and flexor muscles
Description: Patients underwent an isokinetic strength training program with 3 sessions per week during five weeks.~Program consists of excentric contraction of knee flexor and extensor muscles (4 x 7 Contractions at 30°/s) and concentric contractions at maximal speed where patients can perform 40% of his maximal isometric torque for knee flexor and extensor muscles (2x10 for knee flexors and 2x10 for knee extensors)
Study: NCT06260722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Administered SC.
Study: NCT06530823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib and Durvalumab
Description: Pemigatinib combined with Durvalumab Pemigatinib: 13.5mg, oral administration, once daily, swallow the entire tablet with or without food. Take for 2 weeks and then discontinue for 1 week. Durvalumab: 1500mg, intravenous infusion, once every three weeks. Each infusion should take over 60 minutes.
Study: NCT05634538

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic-assisted PCI with Corpath GRX® System
Description: The CorPath GRX System is intended for use in the remote delivery and manipulation of guidewires and rapid exchange catheters, and remote manipulation of guide catheters during percutaneous coronary interventions (PCI).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard PCI
Description: Percutaneous coronary intervention (PCI) is a procedure used to treat the blockages in a coronary artery; it opens up narrowed or blocked sections of the artery, restoring blood flow to the heart. This arm will be completed without robotic assistance.
Study: NCT05991752

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ROMA score evaluation
Description: Every 4 months, for 3 years, patients in the experimental group will done a biological examination based on assessment of the ROMA score (CA125+HE4 assay).
Study: NCT06176963

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SB11 PFS
Description: SB11 provided in a pre-filled syringe (PFS) containing 0.5 mg ranibizumab in 0.05 mL for ITV injection
Study: NCT04790318

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-incisional Quadratus lumborum block
Description: patients will receive combined general anesthesia and quadratus lumborum block (trans-incisional) with 0.5 mL/kg of bupivacaine 0.2 %. with maximum volume was limited to 20 ml

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: patients will receive combined general anesthesia and caudal analgesia (just after wound closure) with 1.25 mL/kg of bupivacaine 0.2 % (three parts 0.25 % bupivacaine to one part saline.
Study: NCT05634395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity tracker
Description: Participants will receive a Withings Steel activity tracker (Withings, Issy-les-Moulineaux, France), which they will be asked to wear 24 hours per day throughout the whole intervention (12 months). At baseline, the Withings Health Mate mobile phone application will be downloaded onto each participant's smartphone or tablet. The clinical research assistant will instruct the participant in the use of the activity tracker. The participant will then accept and activate the sharing of the data collected with the secure server dedicated to the GrannyFit study at the Institut Curie. Participants will be asked to synchronize the activity tracker regularly (ideally daily) via Bluetooth with the Withings Health Mate application, for automatic transfer of the data to the secure GrannyFit space.
Study: NCT06164119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual treatment with osteopathic techniques and nutritional treatment
Description: manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques) and nutritional treatment (personalized Mediterranean Diet)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual treatment with osteopathic techniques and nutritional treatment
Description: manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques) and nutritional treatment (personalized Mediterranean Diet)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual treatment with osteopathic techniques
Description: manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual treatment with osteopathic techniques
Description: manual treatment with osteopathic techniques (8 once-a-week manual treatments with osteopathic techniques)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutritional treatment
Description: nutritional treatment (personalized Mediterranean Diet)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutritional treatment
Description: nutritional treatment (personalized Mediterranean Diet)
Study: NCT05018871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous adipose derived mesenchymal stem cells
Description: cultured autologous adult adipose derived mesenchymal stem cells
Study: NCT05267249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autotransplantation and Apicoectomy
Description: Autotransplantation of a mature teeth with simultaneous extra-oral root-end resectoin
Study: NCT05809232

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CARES-guided Group
Description: Participants randomised to the CARES-guided arm will have their CARES-score calculated and entered into the Pre-Anesthesia Assessment electronic form within the Electronic Medical Records (EMR). This score and its relevant advisories will be prominently displayed on this electronic form. (Participants on this arm will receive this intervention in addition to the routine practice).
Study: NCT05730361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ScTIL injection
Description: Peripheral blood mononuclear cells (PBMCs) obtained via apheresis are used for cell preparation. PD-1 positive T cells are isolated from PBMCs, are transduced with lentivirus loaded with enhanced receptor and superamplification factor, and cell number are amplified. The obtained ScTIL is used for one-time intravenous infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ScTIL injection and B lymphocytes adjuvant
Description: B lymphocyte are also isolated from PBMCs. If the percentage of subject's B lymphocyte in total lymphocytes is \> 5%, the autologous B lymphocyte adjuvant will be prepared. If this percentage is ≤ 5%, PBMCs will be collected from haploidentical donor of the subject via apheresis, and B lymphocyte will be isolated for preparation of allogeneic B lymphocyte adjuvant.
Study: NCT05312775

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double-layer uterine closure
Description: In the intervention group, double-layer closure of the uterus will be performed using unlocked multifilament continuous running sutures for both layers and the endometrial layer will be included in the first layer. The second layer is a continuous running suture that imbricates the first layer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-layer uterine closure
Description: The control group will receive a single-layer closure using unlocked continuous running multifilament sutures and the endometrial layer will be included
Study: NCT04880304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer Heading
Description: A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soccer Heading
Description: A standardized and reliable soccer heading protocol will be used for the experiment. A triaxial accelerometer embedded in a head-band pocket and positioned directly below the external occipital protuberance (inion) to monitor linear and rotational head accelerations. A JUGS soccer machine will be used to simulate a soccer throw-in with a standardized ball speed of 25mph. The ball speed is similar to when soccer players make a long throw-in from the sideline to mid-field. Soccer players frequently perform this maneuver during practice and games. Subjects will stand approximately 40ft away from the machine to perform the heading. Participants perform 20 standing headers with 1 header per 30 seconds. The subjects will be instructed to direct the ball back toward the JUGS soccer machine in the air.
Study: NCT05574127

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Sessions for both arms (BP \& SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~* Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~* Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Psychotherapy
Description: Sessions for both arms (BP \& SP) will be administered remotely via video-conference and/or telephone (per patient preference) at the following timeline:~* Full participants (not training cases): Ten sessions (30-50 minutes each) will be delivered approximately weekly over a 10-week period (+10 weeks).~* Training case participants: Ten sessions (30-50 minutes each) will be delivered over an approximately 5-week period (+10 weeks).
Study: NCT05584930

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of blood sample
Description: * Visit 1 : At inclusion (day 1 of chemotherapy treatment)~* Visit 2 : Onset of aplasia~* Visit 3a : day 1 of the 1st febrile aplasia~* Visit 3b : day 3 of the 1st febrile episode~* Visit 3c : day 8 of the 1st febrile episode~* Visit 4a : second febrile episode (after 7 days)~* Visit 4b : day 3 of the second febrile episode (after 7 days)
Study: NCT06286527

Intervention type: OTHER
Intervention: anonymous self-administered online questionnaire
Description: proposition to participate through billboards with a QR code leading to the questionnaire.
Study: NCT05162417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: 1mg/ml of Methylene as a solution will be used two times, first immediately after scaling and root planning, second after two weeks of the first treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toluidine Blue O
Description: 1mg/ml of Toluidine blue o as a solution will be used two times, first immediately after scaling and root planning, second after two weeks of the first treatment.
Study: NCT04939233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exoskeleton glove
Description: A robotic hand orthosis (exoskeleton glove) will have been developed that is able to naturalistically bend the finger joints of the individuals based on intuitive voice commands
Study: NCT06445712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental Support Cold Pressor Task
Description: Child will submerge their hand in cold water alone and holding the hand of a parent.
Study: NCT06222450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation Therapy (VRT)
Description: customized VRT home exercise program per standard of care, includes gaze stabilization, habituation, balance and gait exercises, and endurance training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation Therapy (VRT)
Description: customized VRT home exercise program per standard of care, includes gaze stabilization, habituation, balance and gait exercises, and endurance training
Study: NCT05003089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1834845
Description: Tablet, oral.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1830839
Description: Tablet, oral.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Tablet, oral.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral.
Study: NCT05131048

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional group
Description: this group will perform conventional therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental group
Description: this group will perform home based exercises
Study: NCT04986696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLASH therapy
Description: Dose escalation of high dose rate radiotherapy (FLASH therapy) as single dose treatment for skin melanoma metastases that progress locally despite systemic treatments.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLASH therapy
Description: Dose escalation of high dose rate radiotherapy (FLASH therapy) as single dose treatment for skin melanoma metastases that progress locally despite systemic treatments.
Study: NCT05571709

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Resistance training of the lower limbs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Physical activity questionnaire

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Questionnaire
Description: Physical activity questionnaire

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous muscle biopsy
Description: Muscle biopsy of the vastus lateralis (m. quadriceps)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Percutaneous muscle biopsy
Description: Muscle biopsy of the vastus lateralis (m. quadriceps)
Study: NCT05524168

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT for metastatic lesions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Maximum 6 cycles for combined therapy. Camrelizumab maintenance for 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Maximum 6 cycles for combined therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Maximum 6 cycles for combined therapy.
Study: NCT04928950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated charcoal
Description: Activated Charcoal, Powder, USP is carbon that has been treated to create low-volume pores that increase the area available for chemical reactions and adsorption. The most common pharmaceutical uses of activated charcoal is as a purification agent and antitoxin. All Spectrum Chemical USP products are manufactured, packaged and stored under current Good Manufacturing Practices (cGMP) per 21CFR part 211 in FDA registered and inspected facilities.
Study: NCT04747977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-DED
Description: 0.2mg dexamethasone ophthalmic insert

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTX-DED
Description: 0.3mg dexamethasone ophthalmic insert

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OTX-DED
Description: Hydrogel vehicle ophthalmic insert
Study: NCT05172765

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation Device
Description: Low-level, electrical stimulation of the outer ear (LLTS), using a transcutaneous electrical nerve stimulation (TENS) device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation Device
Description: Low-level, electrical stimulation of the outer ear (LLTS), using a transcutaneous electrical nerve stimulation (TENS) device.
Study: NCT04838743

Intervention type: DRUG
Intervention: IDegLira
Description: Patients will be treated with commercially available Xultophy® (IDegLira) in a pre-filled pen injector (FlexTouch®) at the discretion of the treating physician in accordance with the Xultophy® label in Japan.~The decision to initiate treatment with Xultophy® is at the treating physician's discretion according to the approved Xultophy® label in Japan and independent from the decision to include the patient in the study.
Study: NCT06115720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video assisted consent
Description: The intervention group will also be shown the same pre-recorded standard verbal consent, but following this will additionally be shown a specifically recorded video of the anaesthetic process for both GA and RA. This video will aim to communicate the same information as that found in the traditional verbal consent, using an actor undergoing an anaesthetic to provide context.
Study: NCT05187676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen saturation measurement using the IPAM device
Description: Skin oxygen saturation rate will be measured (%) using the non-contact optical device under evaluation called IPAM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous oxygen partial pressure (TcPO2) using the PeriFlux6000 device
Description: Skin TcPO2 will be measured (mmHg) using the reference device called PeriFlux6000
Study: NCT06423898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental regimen
Description: Continuous intravenous antibiotic infusion during 42 days for Infective Endocarditis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control regimen
Description: Intermittent intravenous antibiotic infusion during 42 days for Infective Endocarditis
Study: NCT06574581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADSC01
Description: The initial 3 subjects will receive low-dose AD-MSC (1x10E6 cells/kg) infusion therapy only once; if no adverse events after 4 weeks, the next 4-7 subjects will receive medium-dose AD-MSC (1x10E6 cells/kg) infusion therapy twice; if no adverse events after 4 weeks of the last infusion, the next 8-10 subjects will receive high-dose AD-MSC (1x10E6 cells/kg) infusion therapy three times.
Study: NCT05463380

Intervention type: OTHER
Intervention: standard of care
Description: The patient will be treated following the satndard of care in the participating units
Study: NCT06436911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVIGENIX VAX- 002
Description: ENTVAX-001-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVIGENIX VAX- 002
Description: ENTVAX-001-01
Study: NCT05571709

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sample
Description: Venous blood sample

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Blood sample
Description: Venous blood sample
Study: NCT06044415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JWH018
Description: A vaporized dose of 7.5 mg of JWH-018 will be inhaled by the participants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non-active control (no substance)
Description: Participants will inhale from a vaporizer with an empty chamber.
Study: NCT05251337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils
Description: Participants will receive Wyndmere Naturals, Inc. aromatherapy patches. The hydrogel adhesive patches are infused with essential oil for inhaled aromatherapy treatment. The aromatherapy patches provide an occlusive barrier that is hypoallergenic, allowing essential oils to be inhaled without coming in direct contact with the skin. Participants indicating nausea/vomiting is their symptom of concern will receive peppermint aromatherapy patches (or mandarin if peppermint sensitivity). Participants indicating anxiety is their symptom of concern will receive lavender aromatherapy patches.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils
Description: Participants will receive Wyndmere Naturals, Inc. aromatherapy patches. The hydrogel adhesive patches are infused with essential oil for inhaled aromatherapy treatment. The aromatherapy patches provide an occlusive barrier that is hypoallergenic, allowing essential oils to be inhaled without coming in direct contact with the skin. Participants indicating nausea/vomiting is their symptom of concern will receive peppermint aromatherapy patches (or mandarin if peppermint sensitivity). Participants indicating anxiety is their symptom of concern will receive lavender aromatherapy patches.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients assigned to either control group (nausea/vomiting or anxiety) will receive Wyndmere Naturals non-scented patches (i.e., blank hydrogel adhesive patches without essential oil infusion).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients assigned to either control group (nausea/vomiting or anxiety) will receive Wyndmere Naturals non-scented patches (i.e., blank hydrogel adhesive patches without essential oil infusion).
Study: NCT05988177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrimycin tablets
Description: Carrimycin tablets are administered 400mg a day orally for 7 days.
Study: NCT06247878

Intervention type: DEVICE
Intervention: Skiin underwear chest band
Description: Participants will be asked to wear a skiin underwear chest band during a polysomnography test.
Study: NCT05952583

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Additional ultrasound measurements during pregnancy